Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

81 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Antipsychotics on Appetite Regulation

NCT00903916

Psychotic Disorders

COMPLETED

Assessment of a Weight Management Program for Weight Gain in Patients With Schizophrenia

NCT00485823

Schizophrenic Disorders

COMPLETED PHASE4

Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder

NCT00095524

Body Weight Change Schizophrenia Schizoaffective Disorder +1 more

COMPLETED PHASE3

Energy Homeostasis Under Treatment With Atypical Antipsychotics

NCT00148564

Schizophrenia

COMPLETED PHASE4

Body Mass Index (BMI) and Metabolic Changes Following Switch to Aripiprazole From Olanzapine, Risperidone and Quetiapine

NCT00312598

Schizophrenia Schizoaffective Disorder Schizophreniform Disorder +1 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an observational study. 2 Self-report questionnaires assessing changes of appetite and eating behaviors after medication are applied to patients who have been receiving one of the three atypical antipsychotics. We are going to compare changes of appetite and eating behaviors after medication between three atypical antipsychotics and investigate the association between changes of appetite and eating behaviors and changes of weight after medication.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Schizoaffective Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Risperidone

Receiving risperidone treatment

No interventions assigned to this group

Olanzapine

Receiving olanzapine treatment

No interventions assigned to this group

Aripiprazole

Receiving aripiprazole

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients meeting the DSM-IV criteria of schizophrenia, schizophreniform disorder, or schizoaffective disorder
2. Male and female patients aged 19\~59
3. Patients receiving monotherapy with one of the three AAPs, i.e., olanzapine, risperidone, and aripiprazole for more than two and less than 24 months
4. Patients who had at least one-week antipsychotics-free periods before starting the above antipsychotics
5. Clinically stable and able to complete the questionnaires
6. Patients who sufficiently understand the objective of the study and sign informed consent form

Exclusion Criteria

1. Patients having any medical illness or taking any medicine affecting appetite and body weight
2. Patients with severe and unstable medical, neurological or systemic illnesses
3. Patients having any comorbid psychiatric disorders including substance use disorders and eating disorders.
4. Pregnant or breast-feeding women

Minimum Eligible Age

19 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No